SCHEMBL13628116

SCHEMBL13628116

COC(=O)c1cccc(CN2C(=O)/C(=N/O)c3ccc(-c4ccsc4)cc32)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.47
ROCK2 O75116 1/20 0.44
ROCK1 Q13464 1/20 0.44
MAPT P10636 5/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GSK3B P49841 1/20 0.41
POLB P06746 2/20 0.40
GAA P10253 1/20 0.40
TP53 P04637 1/20 0.40
THRB P10828 1/20 0.40
TGM2 P21980 1/20 0.39
CD74 P04233 1/20 0.39
MIF P14174 1/20 0.39
CHRM5 P08912 1/20 0.39
ABHD6 Q9BV23 1/20 0.38
IDO1 P14902 1/20 0.38
LOXL2 Q9Y4K0 1/20 0.38
TNIK Q9UKE5 1/20 0.38
NR4A2 P43354 1/20 0.37
CYP4F2 P78329 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13628107 0.85 TRPA1 (0.50) TRPA1ROCK2ROCK1MAPTL3MBTL1
SCHEMBL13628102 0.85 TRPA1 (0.48) TRPA1ROCK2ROCK1MAPTL3MBTL1
SCHEMBL13628096 0.85 TRPA1 (0.47) TRPA1ROCK2ROCK1MAPTL3MBTL1
SCHEMBL13910829 0.82 TRPA1 (0.47) TRPA1ROCK2ROCK1MAPTL3MBTL1
SCHEMBL13628131 0.82 TRPA1 (0.47) TRPA1ROCK2ROCK1MAPTL3MBTL1
SCHEMBL13910942 0.81 TRPA1 (0.51) TRPA1ROCK2ROCK1MAPTL3MBTL1
SCHEMBL13628123 0.81 TRPA1 (0.51) TRPA1ROCK2ROCK1MAPTL3MBTL1
SCHEMBL13628117 0.78 NR4A2 (0.39) MAPTNR4A2
SCHEMBL13637451 0.74 TRPA1 (0.45) TRPA1ROCK2ROCK1MAPTL3MBTL1
SCHEMBL9172948 0.73 CYP4F2 (0.58) LOXL2NR4A2CYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 TRPA1 4561/4885ROCK2 246/4885ROCK1 214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.